CHADDS FORD, PA and WINNERISH, UK--(MARKET WIRE)--Aug 16, 2007 -- Endo Pharmaceuticals Inc., a wholly owned subsidiary of Endo Pharmaceuticals Holdings Inc. (NasdaqGS:ENDP - News), and Vernalis pls (LSE:VER.L - News) today announced that the U.S. Food and Drug Administration has requested an extension of the August 19, 2007 review date in order to have more time to review the supplemental New Drug Application for FROVA® (frovatriptan succinate) 2.5 mg tablets for the additional indication as short-term (six days) prevention of menstrual migraine.
